CD34+ cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina

CD34+ cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina

Abstract Patients with refractory angina who are suboptimal candidates for further revascularization have improved exercise time, decreased angina frequency, and reduced major adverse cardiac events with intramyocardial delivery of CD34+ cells. However, the effect of CD34+ cell therapy on health car...

Full description

Bibliographic Details
Main Authors: Grace L. Johnson, Timothy D. Henry, Thomas J. Povsic, Douglas W. Losordo, Ross F. Garberich, Larissa I. Stanberry, Craig E. Strauss, Jay H. Traverse
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:Stem Cells Translational Medicine
Subjects:
CD34+ stem cells
cost analysis
major adverse cardiac events
refractory angina
Online Access:https://doi.org/10.1002/sctm.20-0046

Internet

https://doi.org/10.1002/sctm.20-0046

Similar Items